NantOmics
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
9920 Jefferson Blvd, Culver City, Califo...Phone Number
(310) 883-1300Website
www.nantomics.comRevenue
$5.5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About NantOmics
NantOmics is a leader in molecular testing, specializing in the detection of genomic and proteomic alterations in cancer to inform personalized treatment options. Utilizing an integrated panomic approach, the company combines DNA sequencing, RNA sequencing, and quantitative proteomics to provide comprehensive molecular profiles of patients' tumors. Their proprietary analytical platform delivers actionable intelligence and decision support for cancer patients and their healthcare providers. NantOmics aims to enhance precision medicine by identifying targeted drugs that align with specific molecular alterations in individual tumors.Explore more
NantOmics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NantOmics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when NantOmics launches new products
Click to see if NantOmics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once NantOmics has new funding data
NantOmics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on NantOmics recently announced quarterly report
Check if NantOmics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if NantOmics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at NantOmics
Recommended Actions
Reach out to Masked Content who joined NantOmics as Masked Content
Find more new buyers
Compare Similar Companies to NantOmics
Compare insights from companies similar to NantOmics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NantOmics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
NantOmics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about NantOmics.
NantOmics financials insights
Gather financial insights about NantOmics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Multiple Rounds
$260.9M
NantOmics Tech Stack
A closer look at the technologies used by NantOmics
See more technologies
NantOmics News & Media
PolyPid Announces Publication of Animal Model Studies in 2022 ASCO Annual Meeting Abstract Demonstrating that Locally Administered OncoPLEX Potentially Decreases the Likelihood of Tumor Recurrence with Reduced Side Effects
PETACH TIKVA, Israel, June 01, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that animal studies related to OncoPLEX, the Company’s lead intra-tumoral product candidate in oncology applied as a paste to the resection bed during surgery, have been published in an abstract in the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting Abstract Book. The abstract, reductImmunityBio and NantOmics Announce Clinical Validation of a Proprietary Method to Identify Unique Targets for Immunotherapy in Individual Breast Cancer Patients
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a publicly traded immunotherapy company , and privately-held NantOmics today announced publication of a stepwise approach or “pipeline” for identification and validation of neoepitope and neoepitope-reactive T cells from individual patients. The identification of neoepitopes—short peptide sequences that are mutated in tumors and are capable of generating an immune response—provides critical support in the successful developCombination of Deep-Learning Models Provides Significant Risk-Assessment of Survival in Pancreatic Cancer Patients, Holding Promise as a Prognostic Technology
CULVER CITY, Calif.--(BUSINESS WIRE)--NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, presented virtually with NantOmics and ImmunityBio on September 29-30 2020, a session entitled “Deep-learning image-based tumor, stroma and lymphocytes spatial relationships and clinical features that affect survival in pancreatic cancer patients,” at the American Association for Cancer Research (AACR) virtual special conference on pancreatic cancer. This NantNantOmics and NantHealth Announce Results of Proprietary Machine Vision AI Software Study Demonstrating the Ability to Identify Aggressive Subtypes of Breast Cancer From Digital Pathology Images
CULVER CITY, Calif.--(BUSINESS WIRE)--NantOmics, LLC, the leader in molecular analysis, and NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, announced today the publication of a peer-reviewed study in Breast Cancer Research, a Springer Nature journal, on a novel AI technique in breast cancer. The study reports on a novel deep-learning system of digital pathology images and omics data used together to more precisely identify mechanisms of therapy
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NantOmics
Sign Up For FreeTo access detailed company insights
NantOmics is a leader in molecular testing, specializing in the detection of genomic and proteomic alterations in cancer to inform personalized treatment options. Utilizing an integrated panomic approach, the company combines DNA sequencing, RNA sequencing, and quantitative proteomics to provide comprehensive molecular profiles of patients' tumors.... Read More
